MEDP - Medpace Hldgs CEO Sold $3.83M In Company Stock | Benzinga
A substantial insider sell was reported on May 29, by August J Troendle, CEO at Medpace Hldgs (NASDAQ:MEDP), based on the recent SEC filing.
What Happened: Troendle's decision to sell 9,682 shares of Medpace Hldgs was revealed in a Form 4 filing with the U.S. Securities and Exchange Commission on Wednesday. The total value of the sale is $3,828,057.
Monitoring the market, Medpace Hldgs's shares down by 0.04% at $387.82 during Thursday's morning.
All You Need to Know About Medpace Hldgs
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical-device firms. It also offers ancillary services such as bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has over 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati and its operations are principally based in the us, but it also operates in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.
Medpace Hldgs: Financial Performance Dissected
Revenue Growth: Medpace Hldgs's revenue growth over a period of 3 months has been noteworthy. As of 31 March, 2024, the company achieved ...